Trials / Active Not Recruiting
Active Not RecruitingNCT05192382
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Crinetics Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paltusotine | Paltusotine, tablets, once daily by mouth |
| DRUG | Placebo | Placebo, tablets, once daily by mouth |
Timeline
- Start date
- 2021-12-17
- Primary completion
- 2024-01-20
- Completion
- 2028-01-01
- First posted
- 2022-01-14
- Last updated
- 2026-04-01
- Results posted
- 2026-01-13
Locations
57 sites across 15 countries: United States, Argentina, Brazil, Bulgaria, China, France, Germany, Greece, Hungary, India, Israel, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05192382. Inclusion in this directory is not an endorsement.